HK1204921A1 - 依那西普的穩定液體製劑 - Google Patents
依那西普的穩定液體製劑Info
- Publication number
- HK1204921A1 HK1204921A1 HK15105446.2A HK15105446A HK1204921A1 HK 1204921 A1 HK1204921 A1 HK 1204921A1 HK 15105446 A HK15105446 A HK 15105446A HK 1204921 A1 HK1204921 A1 HK 1204921A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- etanercept
- liquid formulation
- stable liquid
- stable
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20110053890 | 2011-06-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1204921A1 true HK1204921A1 (zh) | 2015-12-11 |
Family
ID=46690924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15105446.2A HK1204921A1 (zh) | 2011-06-03 | 2015-06-08 | 依那西普的穩定液體製劑 |
Country Status (26)
Country | Link |
---|---|
US (1) | US10258689B2 (zh) |
EP (1) | EP2714009B1 (zh) |
JP (2) | JP5918850B2 (zh) |
KR (2) | KR101482304B1 (zh) |
CN (2) | CN104623656B (zh) |
AR (1) | AR086658A1 (zh) |
AU (1) | AU2012263100B2 (zh) |
BR (1) | BR112013031112A8 (zh) |
CA (1) | CA2837176C (zh) |
CL (1) | CL2013003461A1 (zh) |
CO (1) | CO6852068A2 (zh) |
EA (1) | EA028947B1 (zh) |
ES (1) | ES2645969T3 (zh) |
HK (1) | HK1204921A1 (zh) |
HU (1) | HUE037031T2 (zh) |
IL (1) | IL229787A (zh) |
MA (1) | MA35186B1 (zh) |
MX (1) | MX354297B (zh) |
MY (1) | MY173907A (zh) |
SG (1) | SG195054A1 (zh) |
TN (1) | TN2013000493A1 (zh) |
TW (2) | TW201540322A (zh) |
UA (1) | UA113172C2 (zh) |
UY (1) | UY34105A (zh) |
WO (1) | WO2012165917A1 (zh) |
ZA (1) | ZA201308659B (zh) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2610839C (en) | 2005-06-14 | 2019-06-25 | Amgen Inc. | Self-buffering protein formulations |
UY34105A (es) * | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
MX2014004725A (es) * | 2011-10-18 | 2015-02-05 | Coherus Biosciences Inc | Formulaciones de etanercept estabilizadas con aminoacidos. |
US10493151B2 (en) | 2011-10-18 | 2019-12-03 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with sodium chloride |
EP2869817A4 (en) * | 2012-07-09 | 2016-04-06 | Coherus Biosciences Inc | STABLE AQUEOUS FORMULATIONS OF ETANERCEPT |
ES2784861T3 (es) | 2012-09-07 | 2020-10-01 | Coherus Biosciences Inc | Formulaciones acuosas estables de adalimumab |
BR112015005161A2 (pt) | 2012-09-11 | 2017-07-04 | Coherus Biosciences Inc | etanercepte corretamente dobrado em alta pureza e excelente rendimento |
JP2014214153A (ja) * | 2013-04-30 | 2014-11-17 | ニプロ株式会社 | 水溶液製剤およびその製造方法 |
WO2014177548A1 (en) * | 2013-05-02 | 2014-11-06 | Mabxience, S.A. | Alternative formulations for tnfr: fc fusion polypeptides |
WO2015056613A1 (ja) * | 2013-10-15 | 2015-04-23 | Meiji Seikaファルマ株式会社 | 安定化されたポリペプチド水性製剤 |
EP3073992A4 (en) * | 2013-11-29 | 2017-09-13 | Ares Trading S.A. | A liquid formulation of a fusion protein comprising tnfr and fc region |
TWI694836B (zh) * | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
EP3148568A4 (en) * | 2014-05-28 | 2018-01-17 | Nono Inc. | Lyophilized formulation of tat-nr2b9c with acetylation scavenger |
JP6480154B2 (ja) * | 2014-11-06 | 2019-03-06 | 持田製薬株式会社 | エタネルセプトの凍結乾燥製剤 |
EP3236990B1 (en) | 2014-12-22 | 2020-09-02 | Ares Trading S.A. | Liquid pharmaceutical composition |
US9672719B1 (en) | 2015-04-27 | 2017-06-06 | State Farm Mutual Automobile Insurance Company | Device for automatic crash notification |
CN104940902B (zh) * | 2015-05-29 | 2018-08-10 | 北京凯因科技股份有限公司 | 一种聚乙二醇集成干扰素变异体的稳定溶液 |
KR101808234B1 (ko) | 2015-06-23 | 2017-12-12 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제 |
WO2017007837A1 (en) * | 2015-07-07 | 2017-01-12 | Nanobio Corporation | Methods and compositions for the stabilizaton of proteins |
MX2015010517A (es) * | 2015-08-13 | 2017-02-13 | Landsteiner Scient S A De C V | Composicion de estabilidad mejorada de etanercept. |
US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
WO2017184880A1 (en) | 2016-04-20 | 2017-10-26 | Coherus Biosciences, Inc. | A method of filling a container with no headspace |
WO2018060210A1 (en) * | 2016-09-27 | 2018-04-05 | Ares Trading S.A. | Liquid pharmaceutical composition |
KR102413592B1 (ko) | 2016-10-21 | 2022-06-27 | 암젠 인크 | 약학적 제형 및 그의 제조 방법 |
KR20180046888A (ko) | 2016-10-28 | 2018-05-09 | (주)셀트리온 | 안정한 약제학적 제제 |
UA123847C2 (uk) * | 2017-03-16 | 2021-06-09 | Лг Кем, Лтд. | Рідка композиція анти-tnf альфа антитіла |
BR112019022873A8 (pt) | 2017-05-02 | 2023-04-11 | Merck Sharp & Dohme | Formulação, e, vaso ou dispositivo de injeção. |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
MX2017013995A (es) * | 2017-10-31 | 2019-05-01 | Probiomed S A De C V | Formulacion farmaceutica estable de una proteina de fusion. |
BR112020012399A2 (pt) * | 2017-12-22 | 2020-11-24 | Samsung Bioepis Co., Ltd. | composição líquida compreendendo antagonista de vegf |
US11253569B2 (en) | 2018-05-03 | 2022-02-22 | Seattle Children's Hospital | Methods of treating Kawasaki Disease |
EP3773468A2 (en) * | 2018-05-04 | 2021-02-17 | Ilkogen Ilaç Sanayi ve Ticaret A.S. | Stable hybrid fc fusion g-csf formulation |
US20210324052A1 (en) * | 2018-10-18 | 2021-10-21 | Merck Sharp & Dohme Corp. | Formulations of anti-rsv antibodies and methods of use thereof |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
NZ256293A (en) | 1992-09-15 | 1997-06-24 | Immunex Corp | Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist |
US5358708A (en) * | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
JP4317010B2 (ja) | 2001-07-25 | 2009-08-19 | ピーディーエル バイオファーマ,インコーポレイティド | IgG抗体の安定な凍結乾燥医薬製剤 |
AU2002363339B2 (en) * | 2001-11-08 | 2008-02-07 | Abbvie Biotechnology Ltd | Stable liquid pharmaceutical formulation of IGG antibodies |
US20030180287A1 (en) | 2002-02-27 | 2003-09-25 | Immunex Corporation | Polypeptide formulation |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
CN100509847C (zh) | 2003-08-01 | 2009-07-08 | 安美基公司 | 结晶肿瘤坏死因子受体2多肽 |
SI21639A (sl) | 2003-12-23 | 2005-06-30 | LEK farmacevtska dru�ba d.d. | Farmacevtski pripravek, ki vsebuje nemicelarne sulfobetaine |
EP1712240B1 (en) * | 2003-12-25 | 2015-09-09 | Kyowa Hakko Kirin Co., Ltd. | Stable water-based medicinal preparation containing antibody |
WO2005082377A1 (ja) * | 2004-03-01 | 2005-09-09 | Ajinomoto Co., Inc. | 抗ヒトTNF-α抗体活性低下抑制剤 |
GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
GB0506708D0 (en) | 2005-04-01 | 2005-05-11 | Queen Mary & Westfield College | Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions |
DE202005006130U1 (de) | 2005-04-12 | 2005-08-25 | Fasys Bauservice Gmbh | Anordnung zur optischen Warnung vor Fahrdrähten |
CN101426527A (zh) * | 2006-02-03 | 2009-05-06 | 米迪缪尼有限公司 | 蛋白质制剂 |
JP2009525986A (ja) * | 2006-02-03 | 2009-07-16 | メディミューン,エルエルシー | タンパク質製剤 |
KR20090021298A (ko) | 2006-06-14 | 2009-03-02 | 임클론 시스템즈 인코포레이티드 | 항-egfr 항체의 동결건조 제제 |
JP5419709B2 (ja) * | 2007-01-09 | 2014-02-19 | ワイス・エルエルシー | 抗il−13抗体製剤およびその使用 |
UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
JP2009155329A (ja) * | 2007-12-07 | 2009-07-16 | Kyowa Hakko Kirin Co Ltd | 上皮細胞成長因子受容体ファミリーに対する抗体またはその機能的断片およびそれらを含有する癌を治療するための医薬組成物 |
PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
WO2010027364A1 (en) * | 2008-09-07 | 2010-03-11 | Glyconex Inc. | Anti-extended type i glycosphingolipid antibody, derivatives thereof and use |
NZ606283A (en) * | 2008-11-28 | 2014-08-29 | Abbvie Inc | Stable antibody compositions and methods for stabilizing same |
SG10201900451SA (en) * | 2009-03-19 | 2019-02-27 | Chugai Pharmaceutical Co Ltd | Pharmaceutical formulation containing improved antibody molecules |
RU2600847C2 (ru) | 2010-05-10 | 2016-10-27 | Интас Биофармасьютикалс Лимитед | Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина |
RU2614257C2 (ru) | 2011-04-20 | 2017-03-24 | Сандоз Аг | СТАБИЛЬНЫЕ ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ СЛИТОГО БЕЛКА TNFR:Fc |
UY34105A (es) | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
-
2012
- 2012-05-29 UY UY0001034105A patent/UY34105A/es not_active Application Discontinuation
- 2012-06-01 JP JP2014513452A patent/JP5918850B2/ja active Active
- 2012-06-01 CA CA2837176A patent/CA2837176C/en active Active
- 2012-06-01 AU AU2012263100A patent/AU2012263100B2/en active Active
- 2012-06-01 WO PCT/KR2012/004369 patent/WO2012165917A1/en active Application Filing
- 2012-06-01 SG SG2013085758A patent/SG195054A1/en unknown
- 2012-06-01 EP EP12793393.5A patent/EP2714009B1/en active Active
- 2012-06-01 BR BR112013031112A patent/BR112013031112A8/pt not_active Application Discontinuation
- 2012-06-01 MY MYPI2013702234A patent/MY173907A/en unknown
- 2012-06-01 TW TW104108045A patent/TW201540322A/zh unknown
- 2012-06-01 CN CN201410790992.2A patent/CN104623656B/zh active Active
- 2012-06-01 MX MX2013014027A patent/MX354297B/es active IP Right Grant
- 2012-06-01 US US14/123,704 patent/US10258689B2/en not_active Expired - Fee Related
- 2012-06-01 UA UAA201313759A patent/UA113172C2/uk unknown
- 2012-06-01 TW TW101119708A patent/TWI548424B/zh active
- 2012-06-01 EA EA201391739A patent/EA028947B1/ru unknown
- 2012-06-01 ES ES12793393.5T patent/ES2645969T3/es active Active
- 2012-06-01 KR KR20120059461A patent/KR101482304B1/ko active IP Right Grant
- 2012-06-01 AR ARP120101960A patent/AR086658A1/es not_active Application Discontinuation
- 2012-06-01 CN CN201280026919.7A patent/CN103619324A/zh active Pending
- 2012-06-01 HU HUE12793393A patent/HUE037031T2/hu unknown
-
2013
- 2013-11-19 ZA ZA2013/08659A patent/ZA201308659B/en unknown
- 2013-11-25 TN TNP2013000493A patent/TN2013000493A1/fr unknown
- 2013-12-02 CO CO13282255A patent/CO6852068A2/es not_active Application Discontinuation
- 2013-12-03 CL CL2013003461A patent/CL2013003461A1/es unknown
- 2013-12-03 IL IL229787A patent/IL229787A/en active IP Right Grant
- 2013-12-16 MA MA36575A patent/MA35186B1/fr unknown
-
2014
- 2014-08-29 KR KR20140114550A patent/KR20140122213A/ko not_active Application Discontinuation
-
2015
- 2015-06-08 HK HK15105446.2A patent/HK1204921A1/zh unknown
-
2016
- 2016-01-08 JP JP2016002956A patent/JP2016145192A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1204921A1 (zh) | 依那西普的穩定液體製劑 | |
IL255045A0 (en) | A crystal of flumioxazin | |
HK1213174A1 (zh) | 穩定的含水依那西普製劑 | |
HK1208372A1 (zh) | 液體製劑 | |
PT2854768T (pt) | Composições farmacêuticas de pemetrexed | |
EP2737914A4 (en) | LIQUID COLLECTOR | |
SI2691083T1 (sl) | Farmacevtski sestavek sitagliptina | |
EP2683373C0 (de) | Orthomolekulares mittel gegen die folgen von alkoholkonsum | |
IL229677A0 (en) | A liquid pharmaceutical preparation containing nitisinone | |
EP2799149A4 (en) | liquid spraying | |
EP2766469A4 (en) | USE OF FUNGICIDES IN LIQUID SYSTEMS | |
EP2700698A4 (en) | LIQUID CRYSTAL COMPOSITION | |
EP2708123A4 (en) | LIQUID INSECTICIDE COMPOSITION | |
EP2801412A4 (en) | liquid spraying | |
EP2695679A4 (en) | LIQUID ATOMIZATION DEVICE | |
IL259184A (en) | Crystal of flumeoxazine | |
ZA201401031B (en) | Liquid chemical composition | |
EP2785723A4 (en) | DIFLUOROMETHYLATION OF UNSATURATED COMPOUNDS | |
HUP1100272A2 (en) | Pharmaceutical use of silicic acid | |
TWI561617B (en) | Liquid crystal composition | |
IL233878A0 (en) | Liquid dnase i preparations for inhalation | |
AU2011902757A0 (en) | Liquid chemical composition | |
AU2012902062A0 (en) | Liquid Formulation | |
GB201106255D0 (en) | Liquid insecticidal compositions | |
GB201104632D0 (en) | Use of medicament |